JP2011510009A5 - - Google Patents

Download PDF

Info

Publication number
JP2011510009A5
JP2011510009A5 JP2010543200A JP2010543200A JP2011510009A5 JP 2011510009 A5 JP2011510009 A5 JP 2011510009A5 JP 2010543200 A JP2010543200 A JP 2010543200A JP 2010543200 A JP2010543200 A JP 2010543200A JP 2011510009 A5 JP2011510009 A5 JP 2011510009A5
Authority
JP
Japan
Prior art keywords
prodrug
formula
pharmaceutically acceptable
acceptable salt
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010543200A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011510009A (ja
Filing date
Publication date
Priority claimed from US12/352,903 external-priority patent/US8063033B2/en
Application filed filed Critical
Publication of JP2011510009A publication Critical patent/JP2011510009A/ja
Publication of JP2011510009A5 publication Critical patent/JP2011510009A5/ja
Pending legal-status Critical Current

Links

JP2010543200A 2008-01-18 2009-01-14 緑内障、高眼圧、禿頭症及び脱毛症の治療用ベータラクタム Pending JP2011510009A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2217208P 2008-01-18 2008-01-18
US12/352,903 US8063033B2 (en) 2008-01-18 2009-01-13 Therapeutic beta-lactams
PCT/US2009/030894 WO2009091764A2 (en) 2008-01-18 2009-01-14 Therapeutic beta-lactams

Publications (2)

Publication Number Publication Date
JP2011510009A JP2011510009A (ja) 2011-03-31
JP2011510009A5 true JP2011510009A5 (enExample) 2012-03-01

Family

ID=40876971

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010543200A Pending JP2011510009A (ja) 2008-01-18 2009-01-14 緑内障、高眼圧、禿頭症及び脱毛症の治療用ベータラクタム

Country Status (7)

Country Link
US (1) US8063033B2 (enExample)
EP (1) EP2321304A2 (enExample)
JP (1) JP2011510009A (enExample)
AU (1) AU2009205477A1 (enExample)
BR (1) BRPI0906846A2 (enExample)
CA (1) CA2712264A1 (enExample)
WO (1) WO2009091764A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772392B2 (en) * 2005-05-06 2010-08-10 Allergan, Inc. Therapeutic substituted β-lactams
CA2602535A1 (en) * 2005-05-06 2006-11-16 Allergan, Inc. Substituted beta-lactams and their use in medicine
PL2155733T3 (pl) * 2007-05-23 2013-02-28 Allergan Inc Cykliczne laktamy do leczenia jaskry lub podwyższonego ciśnienia śródgałkowego
US8440819B2 (en) * 2008-02-22 2013-05-14 Allergan, Inc. Therapeutic substituted beta-lactams
US8202855B2 (en) * 2008-03-04 2012-06-19 Allergan, Inc Substituted beta-lactams

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) * 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) * 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) * 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
GB8329559D0 (en) * 1983-11-04 1983-12-07 Erba Farmitalia Furyl derivatives of 16-substituted prostaglandins preparations
JPH08504765A (ja) 1992-12-16 1996-05-21 アグロン・ファーマシュウティカルズ・インコーポレーテッド 抗増殖性の置換5−チアピリミジノンおよび5−セレノピリミジノン化合物
US5462968A (en) * 1994-01-19 1995-10-31 Allergan, Inc. EP2 -receptor agonists as agents for lowering intraocular pressure
US5698598A (en) * 1995-08-04 1997-12-16 Allergan EP2 -receptor agonists as agents for lowering intraocular pressure
US6090847A (en) * 1997-11-21 2000-07-18 Allergan Sales, Inc. EP2 -receptor agonists as neuroprotective agents for the eye
US6437146B1 (en) * 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
EA200300379A1 (ru) * 2000-11-27 2003-08-28 Пфайзер Продактс Инк. Селективные агонисты рецептора ep4 в лечении остеопороза
JP2004521954A (ja) * 2001-07-16 2004-07-22 エフ.ホフマン−ラ ロシュ アーゲー Ep4受容体作用薬としてのプロスタグランジン類似体
ES2246419T3 (es) * 2001-11-05 2006-02-16 Allergan, Inc. Analogos de omega-cicloalquil-17-heteroaril-prostaglandina e2 como agonistas del receptor ep-2.
ATE336247T1 (de) * 2002-03-18 2006-09-15 Pfizer Prod Inc Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten
US7091231B2 (en) * 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
CA2602535A1 (en) * 2005-05-06 2006-11-16 Allergan, Inc. Substituted beta-lactams and their use in medicine
WO2006121822A1 (en) 2005-05-06 2006-11-16 Allergan, Inc. USE OF β-LACTAMS FOR THE TREATMENTOF IBD AND GLAUCOMA
US7772392B2 (en) * 2005-05-06 2010-08-10 Allergan, Inc. Therapeutic substituted β-lactams
US7674786B2 (en) * 2005-05-06 2010-03-09 Allergan, Inc. Therapeutic β-lactams
US7427685B2 (en) * 2005-12-06 2008-09-23 Allergan, Inc. Therapeutic substituted cyclopentanes
US20070254920A1 (en) * 2006-04-26 2007-11-01 Aerie Pharmaceuticals, Inc. Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
US8202855B2 (en) * 2008-03-04 2012-06-19 Allergan, Inc Substituted beta-lactams

Similar Documents

Publication Publication Date Title
JP2021534124A5 (enExample)
JP2009143956A5 (enExample)
JP2011517453A5 (enExample)
JP2011523952A5 (enExample)
JP2011509309A5 (enExample)
JP2009504763A5 (enExample)
JP2013518832A5 (enExample)
JP2013507423A5 (enExample)
JP2014505723A5 (enExample)
JP2011519910A5 (enExample)
JP2013512277A5 (enExample)
JP2007302689A5 (enExample)
JP2018135343A5 (enExample)
JP2013514980A5 (enExample)
JP2010520243A5 (enExample)
JP2013515037A5 (enExample)
JP2019519593A5 (enExample)
JP2010510232A5 (enExample)
RU2011112684A (ru) АГЕНТ, СПОСОБСТВУЮЩИЙ РОСТУ ВОЛОС, СОДЕРЖАЩИЙ В КАЧЕСТВЕ АКТИВНОГО ИНГРЕДИЕНТА ПРОИЗВОДНОЕ 15,15-ДИФТОРПРОСТАГЛАНДИНА F2α
JP2008517020A5 (enExample)
JP2012513982A5 (enExample)
JP2010534246A5 (enExample)
JP2010514734A5 (enExample)
JP2008521908A5 (enExample)
RU2009128970A (ru) Производные изосорбидмононитрата для лечения кишечных заболеваний